glp-1 incretin is released from the small intestine after meal ingestion and Incretins as Multi–Disease State Treatments

GLP-1 receptor agonists include semaglutide, dulaglutide, and liraglutide, used for type 2 diabetes and weight management

The list below summarises events reported in published trial data it is not a complete safety profile

Precedent comes from the Cell and Gene Therapy Access Model, which requires participating states to meet coverage and prior authorization standards to get negotiated prices for sickle cell therapies

Once-monthly maridebart cafraglutide for the treatment of obesity - A phase 2 trial

Patients treated with GLP-1 RAs should therefore understand they will need to continue using them long-term

This prevents bacterial growth but does not stop chemical degradation of the peptide